Connect with us
  • Elysium


Daily News Round Up: Tuesday, 19 March



Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

Alzheimer’s drug presents unique challenge for patients with cardiovascular disease

A new Viewpoint article published in JAMA, entitled ” Use of Lecanemab for Patients with Cardiovascular Disease – The Challenge of Uncertainty,” advocates for additional research to improve decision making prior to initiating lecanemab, commercially known as Leqembi, an FDA-approved Alzheimer’s Disease drug. The authors note that in approving lecanemab, the FDA did not advise regarding the risk of concurrent anticoagulation therapy, and that “the Alzheimer’s Association’s Therapeutics Work Group took a more conservative approach and recommended that persons with cerebral amyloid angiopathy and those currently prescribed anticoagulants should not be candidates for lecanemab because the risk of bleeding outweighs the potential benefit.”

Unanticipated complexity in aging brain’s memory decline

Researchers from The University of Texas at Dallas Center for Vital Longevity have discovered that brain correlates of age-related memory decline are more complicated than previously believed, a finding that could affect efforts to preserve cognitive health in older people. The research team found that age-related neural dedifferentiation, marked by a decline in the functional specialisation of different brain regions, is driven by multiple mechanisms.

Subcutaneous infusion pump safe, effective for Parkinson’s treatment

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing symptoms for longer periods of time. The results could lead to additional treatment options for patients with the condition.

Company and financial neuro-rehab news

Phase II Clinical Trials for treating concussion

Oragenics has appointed Dr James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury. ONP-002 is a new chemical entity designed to target the brain through delivery into the nasal cavity and onward to the brain. A 40-patient Phase I study was completed and showed the drug to be safe and well tolerated.

Drug discovery collaboration for Central Nervous System disorders

Sibylla Biotech and Ono Pharmaceutical are entering into a collaboration that will enable access to Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System (CNS) disorders.

Policy news

Legislation for neuroprivacy 

Chile has become the first country in the world to introduce a bill that aims to protect mental privacy in a new age of neurotechology. According to Agencia Brasil PEC 29 was inspired by a proposal from the Neurorights Foundation, in the US, and by a proposal already approved by the Chilean Congress. The publication reports that in the bill, lawmakers point out that the development of neurotechnology brings “hope and great expectation,” especially in medicine, but also creates “a well-founded concern about the ethical and normative limits” of the use of these methods on human beings.